Bromoacetyl bromide | CAS:598-21-0

We serve Bromoacetyl bromide CAS:598-21-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Bromoacetyl bromide

Chemical Name:Bromoacetyl bromide
CAS.NO:598-21-0
Synonyms:Acetyl bromide, bromo-
2-bromoacetyl bromide
Molecular Formula:C2H2Br2O
Molecular Weight:201.84500
 
Physical and Chemical Properties:
Density:2.324;
Melting point:-45oC;
Boiling point:147-150oC;
Flash point:105oC;
Index of Refraction:1.547;
 
Specification:
Appearance:Colorless transparent or yellowish liquid
Purity:≥98.0%
Moisture:≤0.1%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As an intermediate in organic synthesis



Contact us for information like Bromoacetyl bromide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromoacetyl bromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Bromoacetyl bromide Use and application,Bromoacetyl bromide technical grade,usp/ep/jp grade.


Related News: In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.2-(Heptafluoropropoxy)hexafluoropropyl Trifluorovinyl Ether manufacturer Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-ol supplier Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Chroman-4-one vendor Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule.Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule.